A MULTICENTER STUDY TO EXPLORE THE MECHANISM OF ACQUIRED IMMUNE ESCAPE IN PATIENTS WITH METASTATIC CANCER PROGRESSING ON CHECKPOINT INHIBITOR THERAPY
Sponsor: |
Genentech, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR5089 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy. Cancers include: bladder cancer, brain and spinal tumors, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers (cervical cancer, ovarian cancer, uterine (endometrial cancer), kidney cancer/adrenal cancer, liver cancer, lung cancer, skin cancers, melanoma, pancreatic cancer, prostate cancer, sarcomas, stomach cancer, testicular cancer, and thyroid cancer.
This study is closed
Are you 18 years or older? |
Yes |
No |
Are you taking CPI combination therapies with chemotherapy? |
Yes |
No |
Do you have a tissue sample available or are you scheduled for a tumor biopsy soon? |
Yes |
No |